New-onset DM was defined as any adverse event report of DM, or starting glucose-lowering medication,
or a fasting plasma glucose level 7 mmol/L (either 1 or 2 values,
depending on the frequency of measurement in the trial). Dichotomous outcome variables were compared using odds
ratios (ORs) and 95% credible intervals (CIs) by means of network meta-analysis using a Bayesian hierarchical random-effects model.